SJ
Shah Jigneshkumar Ashwin
About Shah Jigneshkumar Ashwin
Data last updated:
Shah Jigneshkumar Ashwin has 15 years in corporate governance. Holds Managing Director and Whole-Time Director roles. Currently with 3 companies, including Asons Pharmaceuticals Private Limited and Purecaps India Private Limited. Formerly with 2 companies, such as Universal Skin Impex Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Managing Director | 02 Sep 2021 | 2021 | Active | |
| Whole-Time Director | 24 Sep 2021 | 2021 | Active | |
| Director | 28 Apr 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Director | 28 Jul 2011 | 2011 | Active | |
| Additional Director | 09 Jun 2025 | 2012 | Under Cirp |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shah Jigneshkumar Ashwin
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shah Jigneshkumar Ashwin
Shah Jigneshkumar Ashwin has 15 years in corporate governance. Holds Managing Director and Whole-Time Director roles. Currently with 3 companies, including Asons Pharmaceuticals Private Limited and Purecaps India Private Limited. Formerly with 2 companies, such as Universal Skin Impex Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Shah Jigneshkumar Ashwin is associated with 3 companies as Managing Director and Whole-Time Director.
Shah Jigneshkumar Ashwin has expertise in General Business, Technology.
Shah Jigneshkumar Ashwin has 15 years in corporate governance.